| Year |
Citation |
Score |
| 2023 |
Mahmood T, Miles JR, Minnier J, Tavori H, DeBarber AE, Fazio S, Shapiro MD. Effect of PCSK9 inhibition on plasma levels of small dense low density lipoprotein-cholesterol and 7-ketocholesterol. Journal of Clinical Lipidology. PMID 37923663 DOI: 10.1016/j.jacl.2023.10.009 |
0.365 |
|
| 2023 |
Chung DW, Platten KC, Ozawa K, Adili R, Pamir N, Nussdorfer F, St John AE, Ling M, Le J, Harris J, Rhoads NM, Wang Y, Fu X, Chen J, Fazio S, et al. Low Density Lipoprotein promotes Microvascular Thrombosis by enhancing von Willebrand Factor Self-association. Blood. PMID 37506337 DOI: 10.1182/blood.2023019749 |
0.376 |
|
| 2023 |
Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, Fazio S, Fras Z, Goodman SG, Harrington RA, Jukema JW, Manvelian G, Pordy R, Ray KK, Scemama M, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. European Heart Journal. PMID 36879424 DOI: 10.1093/eurheartj/ehad144 |
0.318 |
|
| 2022 |
Gu J, Sanchez R, Chauhan A, Fazio S, Wong N. Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update. American Journal of Preventive Cardiology. 10: 100336. PMID 35368909 DOI: 10.1016/j.ajpc.2022.100336 |
0.312 |
|
| 2021 |
Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. European Journal of Preventive Cardiology. 28: 816-822. PMID 34298554 DOI: 10.1177/2047487320915803 |
0.351 |
|
| 2021 |
Velho TAF, Lovell PV, Friedrich SR, Olson CR, Miles J, Mueller PA, Tavori H, Fazio S, Lois C, Mello CV. Divergent low-density lipoprotein receptor (LDLR) linked to low VSV G-dependent viral infectivity and unique serum lipid profile in zebra finches. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33903244 DOI: 10.1073/pnas.2025167118 |
0.32 |
|
| 2020 |
Oleaga C, Hay J, Gurcan E, David LL, Mueller PA, Tavori H, Shapiro MD, Pamir N, Fazio S. Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. Journal of Lipid Research. 62: 100003. PMID 33429337 DOI: 10.1194/jlr.RA120000964 |
0.31 |
|
| 2020 |
Oleaga C, Hay J, Gurcan E, David LL, Mueller PA, Tavori H, Shapiro MD, Pamir N, Fazio S. Insights on the kinetics and dynamics of the furin-cleaved form of PCSK9. Journal of Lipid Research. PMID 33203719 DOI: 10.1194/jlr.RA120000964 |
0.315 |
|
| 2020 |
Boden WE, Baum S, Toth PP, Fazio S, Bhatt DL. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiology. PMID 32959713 DOI: 10.2217/Fca-2020-0106 |
0.358 |
|
| 2020 |
Shapiro MD, Fazio S. Lipoprotein(a): An Enigmatic Sheep in the Lipoprotein Herd. Jacc. Basic to Translational Science. 5: 558-560. PMID 32614936 DOI: 10.1016/J.Jacbts.2020.04.010 |
0.483 |
|
| 2020 |
Zhou Y, Borchelt D, Bauson JC, Fazio S, Miles JR, Tavori H, Notterpek L. Subcellular diversion of cholesterol by gain- and loss-of-function mutations in PMP22. Glia. PMID 32511821 DOI: 10.1002/Glia.23840 |
0.494 |
|
| 2020 |
Pamir N, Fazio S. Lipoprotein(a) Gets Worse. Circulation Research. 126: 1360-1362. PMID 32379575 DOI: 10.1161/Circresaha.120.316980 |
0.483 |
|
| 2020 |
Tavori H, Ormseth MJ, Lilley JS, Papen CR, May-Zhang LS, Davies SS, Linton MF, Fazio S. Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. Journal of Clinical Lipidology. PMID 32376310 DOI: 10.1016/J.Jacl.2020.04.001 |
0.45 |
|
| 2020 |
Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. European Journal of Preventive Cardiology. 2047487320915803. PMID 32276577 DOI: 10.1177/2047487320915803 |
0.479 |
|
| 2020 |
Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. PMID 32052833 DOI: 10.1093/Eurheartj/Ehz962 |
0.4 |
|
| 2020 |
Garg A, Fazio S, Duell PB, Baass A, Udata C, Joh T, Riel T, Sirota M, Dettling D, Liang H, Garzone PD, Gumbiner B, Wan H. Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort. Journal of the Endocrine Society. 4: bvz015. PMID 31993549 DOI: 10.1210/Jendso/Bvz015 |
0.357 |
|
| 2020 |
Fazio S, Linton MF. Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low" Current Controlled Trials in Cardiovascular Medicine. 2: 8-11. PMID 11806766 DOI: 10.1186/cvm-2-1-008 |
0.343 |
|
| 2020 |
Zakai N, Minnier J, Safford MM, Colantonio L, Irvin MM, Fazio S, Cushman M, Howard VJ, Pamir N. Abstract P150: Association of Cholesterol Measures With Coronary Heart Disease Risk in Blacks and Whites in the Reasons for Geographic and Racial Differences in Stroke Study (regards) Circulation. 141. DOI: 10.1161/Circ.141.Suppl_1.P150 |
0.382 |
|
| 2019 |
Toth PP, Fazio S, Wong ND, Hull M, Nichols GA. Risk of Cardiovascular Events in Patients with Hypertriglyceridemia: A Review of Real-World Evidence. Diabetes, Obesity & Metabolism. PMID 31742844 DOI: 10.1111/Dom.13921 |
0.432 |
|
| 2019 |
Zhou Y, Bazick H, Miles JR, Fethiere A, Salihi MAI, Fazio S, Tavori H, Notterpek L. A neutral lipid-enriched diet improves myelination and alleviates peripheral nerve pathology in neuropathic mice. Experimental Neurology. 113031. PMID 31386828 DOI: 10.1016/J.Expneurol.2019.113031 |
0.407 |
|
| 2019 |
Tavori H, Fenton AM, Plubell DL, Rosario S, Yerkes E, Gasik R, Miles J, Bergstrom P, Minnier J, Fazio S, Pamir N. Elevated lipoprotein(a) levels lower ABCA1 cholesterol efflux capacity. The Journal of Clinical Endocrinology and Metabolism. PMID 31220285 DOI: 10.1210/Jc.2018-02708 |
0.505 |
|
| 2019 |
Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: Current status, controversies, and future directions. Trends in Cardiovascular Medicine. PMID 31151804 DOI: 10.1016/J.Tcm.2019.05.007 |
0.428 |
|
| 2019 |
Warden BA, Minnier J, Watts GF, Fazio S, Shapiro MD. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. Journal of Clinical Lipidology. PMID 31130489 DOI: 10.1016/J.Jacl.2019.04.008 |
0.413 |
|
| 2019 |
Zhou Y, Miles JR, Tavori H, Lin M, Khoshbouei H, Borchelt D, Bazick H, Landreth GE, Lee S, Fazio S, Notterpek L. PMP22 regulates cholesterol trafficking and ABCA1-mediated cholesterol efflux. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 31061090 DOI: 10.1523/Jneurosci.2942-18.2019 |
0.456 |
|
| 2019 |
Mueller PA, Zhu L, Tavori H, Huynh KT, Giunzioni I, Stafford JM, Linton MF, Fazio S. Response by Mueller et al to Letter Regarding Article, "Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages". Circulation. 139: 1983-1984. PMID 30986111 DOI: 10.1161/Circulationaha.119.039682 |
0.418 |
|
| 2019 |
Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. Journal of the American Heart Association. 8: e010932. PMID 30755061 DOI: 10.1161/Jaha.118.010932 |
0.427 |
|
| 2019 |
Weitz JI, Fazio S. Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. Circulation Research. 124: 351-353. PMID 30702992 DOI: 10.1161/Circresaha.118.314576 |
0.411 |
|
| 2019 |
Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, Wojcik C, Fazio S, Shapiro MD. Application of PCSK9 Inhibitors in Practice. Circulation Research. 124: 32-37. PMID 30605414 DOI: 10.1161/Circresaha.118.314191 |
0.351 |
|
| 2018 |
O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, et al. Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial. Circulation. PMID 30586750 DOI: 10.1161/Circulationaha.118.037184 |
0.392 |
|
| 2018 |
Sandesara PB, Virani SS, Fazio S, Shapiro MD. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews. PMID 30312399 DOI: 10.1210/Er.2018-00184 |
0.493 |
|
| 2018 |
Ballantyne CM, Bhatt DL, Cannon CP, Fazio S, Sabatine MS. Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. The American Journal of Cardiology. PMID 30301542 DOI: 10.1016/J.Amjcard.2018.08.020 |
0.371 |
|
| 2018 |
Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol. Diabetes, Obesity & Metabolism. PMID 30225881 DOI: 10.1111/Dom.13537 |
0.386 |
|
| 2018 |
Zhu L, Luu T, Emfinger CH, Parks BA, Shi J, Trefts E, Zeng F, Kuklenyik Z, Harris RC, Wasserman DH, Fazio S, Stafford JM. CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. Diabetes. PMID 30213825 DOI: 10.2337/Db18-0474 |
0.455 |
|
| 2018 |
Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. Journal of Clinical Lipidology. PMID 30100157 DOI: 10.1016/J.Jacl.2018.07.003 |
0.368 |
|
| 2018 |
Nichols GA, Philip S, Reynolds K, Granowitz CB, O'Keeffe-Rosetti M, Fazio S. Comparison of Medical Care Utilization and Costs Among Patients With Statin-Controlled Low-Density Lipoprotein Cholesterol With Versus Without Hypertriglyceridemia. The American Journal of Cardiology. PMID 30086877 DOI: 10.1016/J.Amjcard.2018.06.029 |
0.331 |
|
| 2018 |
Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology. 72: 314-329. PMID 30012326 DOI: 10.1016/J.Jacc.2018.04.054 |
0.425 |
|
| 2018 |
Wu MD, Moccetti F, Brown E, Davidson BP, Atkinson T, Belcik JT, Giraud G, Duell PB, Fazio S, Tavori H, Tsimikas S, Lindner JR. Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia. Jacc. Cardiovascular Imaging. PMID 29909101 DOI: 10.1016/J.Jcmg.2018.05.001 |
0.304 |
|
| 2018 |
Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol. The Journal of Clinical Endocrinology and Metabolism. PMID 29850861 DOI: 10.1210/Jc.2018-00470 |
0.451 |
|
| 2018 |
Mueller PA, Zhu L, Tavori H, Huynh K, Giunzioni I, Stafford JM, Linton MF, Fazio S. Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases CCR7 Expression in Plaque Macrophages. Circulation. PMID 29794082 DOI: 10.1161/Circulationaha.117.031702 |
0.487 |
|
| 2018 |
Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials. Circulation Research. 122: 1420-1438. PMID 29748367 DOI: 10.1161/Circresaha.118.311227 |
0.315 |
|
| 2018 |
Niswender KD, Fazio S, Gower BA, Silver HJ. Balanced high fat diet reduces cardiovascular risk in obese women although changes in adipose tissue, lipoproteins, and insulin resistance differ by race. Metabolism: Clinical and Experimental. 82: 125-134. PMID 29382504 DOI: 10.1016/J.Metabol.2018.01.020 |
0.314 |
|
| 2018 |
Kaseda R, Tsuchida Y, Yang HC, Yancey PG, Zhong J, Tao H, Bian A, Fogo AB, Linton MRF, Fazio S, Ikizler TA, Kon V. Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism. Bmc Nephrology. 19: 17. PMID 29374468 DOI: 10.1186/S12882-018-0814-8 |
0.401 |
|
| 2018 |
Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, et al. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology. 71: 177-192. PMID 29325642 DOI: 10.1016/J.Jacc.2017.11.014 |
0.332 |
|
| 2018 |
Veerakul G, Limwongse C, D. Shapiro M, Fazio S, Chaothawee L, Chaishotiranant N. Result of Genetic Analysis in FH Case The Bangkok Medical Journal. 14: 129-130. DOI: 10.31524/Bkkmedj.2018.09.022 |
0.334 |
|
| 2018 |
D. Shapiro M, Fazio S. Familial Hypercholesterolemia: Use of Registries, Biobanks, and Cohort Studies To Improve its Diagnosis and Management in Non-Western Populations The Bangkok Medical Journal. 14: 63-68. DOI: 10.31524/Bkkmedj.2018.02.012 |
0.383 |
|
| 2018 |
Veerakul G, D. Shapiro M, Fazio S, Chaothawee L, Suchato C, Chaishotiranant N, Indrabhinduwat M, Chamsaad P, Khajornyai A, Kawkaew T, Sindhuwanna U. Aborted Sudden Cardiac Death in Young Man with Familial Hypercholesterolemia: A Case Report and Review of The Literature The Bangkok Medical Journal. 14: 57-62. DOI: 10.31524/Bkkmedj.2018.02.011 |
0.331 |
|
| 2018 |
NICHOLS G, PHILIP S, GRANOWITZ CB, REYNOLDS K, FAZIO S. Increased Cardiovascular Risk in Patients with Diabetes, Statin-Controlled LDL Cholesterol, and Residual Hypertriglyceridemia Diabetes. 67: 1485-P. DOI: 10.2337/Db18-1485-P |
0.356 |
|
| 2018 |
Fenton AM, Minnier J, Plubell DL, Bergstrom P, Tavori H, Fazio S, Pamir N. Abstract 561: Reduced Serum Efflux Capacity Associates With Elevated Plasma Lp(a) Levels Arteriosclerosis, Thrombosis, and Vascular Biology. 38. DOI: 10.1161/Atvb.38.Suppl_1.561 |
0.323 |
|
| 2018 |
Plubell D, Predazzi I, McKelvey J, Clarke J, Letaw J, Raboin MJ, Wilmarth PA, Curran J, Fazio S, Pamir N, Vinson A. Abstract 180: Missense Mutations in ABCA1 and CETP Associate with Changes in the HDL Proteome in Primate Half-Sibs Discordant for HDL Cholesterol Levels Arteriosclerosis, Thrombosis, and Vascular Biology. 38. DOI: 10.1161/Atvb.38.Suppl_1.180 |
0.403 |
|
| 2018 |
De Stefano D, Baragetti A, Baragetti A, Macrì N, Tavori H, Fazio S, Catapano A. Binding of PCSK9 to circulating LDL: Effect of PCSK9 monoclonal antibodies on the LDL-bound PCSK9? Atherosclerosis. 275: e101. DOI: 10.1016/J.Atherosclerosis.2018.06.276 |
0.341 |
|
| 2017 |
Lilley JS, Linton MF, Kelley JC, Graham TB, Fazio S, Tavori H. A case of severe acquired hypertriglyceridemia in a 7-year-old girl. Journal of Clinical Lipidology. PMID 28916403 DOI: 10.1016/J.Jacl.2017.08.003 |
0.3 |
|
| 2017 |
Lietman CD, Segedy AK, Li B, Fazio S, Atkinson JB, Linton MF, Young PP. Loss of SPRR3 in ApoE-/- mice leads to atheroma vulnerability through Akt dependent and independent effects in VSMCs. Plos One. 12: e0184620. PMID 28886156 DOI: 10.1371/Journal.Pone.0184620 |
0.378 |
|
| 2017 |
Kaufman TM, Duell PB, Purnell JQ, Wójcik C, Fazio S, Shapiro MD. Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities. Circulation Research. 121: 499-501. PMID 28819040 DOI: 10.1161/Circresaha.117.311532 |
0.465 |
|
| 2017 |
Fazio S, Minnier J, Shapiro MD, Tsimikas S, Tarugi P, Averna MR, Arca M, Tavori H. Threshold Effects of Circulating Angiopoietin-like 3 Levels on Plasma Lipoproteins. The Journal of Clinical Endocrinology and Metabolism. PMID 28633452 DOI: 10.1210/Jc.2016-4043 |
0.363 |
|
| 2017 |
Edmiston JB, Brooks N, Tavori H, Minnier J, Duell B, Purnell JQ, Kaufman T, Wojcik C, Voros S, Fazio S, Shapiro MD. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. Journal of Clinical Lipidology. 11: 667-673. PMID 28506388 DOI: 10.1016/J.Jacl.2017.03.001 |
0.493 |
|
| 2017 |
Shapiro MD, Fazio S. Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering. Nature Reviews. Cardiology. PMID 28470176 DOI: 10.1038/Nrcardio.2017.66 |
0.37 |
|
| 2017 |
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. PMID 28444290 DOI: 10.1093/Eurheartj/Ehx144 |
0.402 |
|
| 2017 |
Shapiro MD, Fazio S. PCSK9 and Atherosclerosis - Lipids and Beyond. Journal of Atherosclerosis and Thrombosis. PMID 28302950 DOI: 10.5551/Jat.Rv17003 |
0.429 |
|
| 2017 |
Shapiro MD, Fazio S. Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. F1000research. 6: 134. PMID 28299190 DOI: 10.12688/F1000Research.9845.1 |
0.464 |
|
| 2017 |
Edmiston B, Brooks N, Minnier J, Wojcik C, Duell BP, Purnell JQ, Kaufman T, Tavori H, Fazio S, Shapiro M. Discordant Response Of Low Density Lipoprotein Cholesterol And Lp(A) Levels To Monoclonal Antibodies Targeting Proprotein Convertase Subtilisin/Kexin Type 9 Journal of the American College of Cardiology. 69: 1665. DOI: 10.1016/S0735-1097(17)35054-4 |
0.475 |
|
| 2016 |
Ormseth MJ, Yancey PG, Yamamoto S, Oeser AM, Gebretsadik T, Shintani A, Linton MF, Fazio S, Davies SS, Roberts LJ, Vickers KC, Raggi P, Kon V, Stein CM. Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. Ijc Metabolic & Endocrine. 13: 6-11. PMID 28243578 DOI: 10.1016/J.Ijcme.2016.08.002 |
0.426 |
|
| 2016 |
Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. The New England Journal of Medicine. 375: 2144-2153. PMID 27959767 DOI: 10.1056/Nejmoa1604304 |
0.394 |
|
| 2016 |
Fazio S, Pamir N. HDL Particle Size and Functional Heterogeneity. Circulation Research. 119: 704-7. PMID 27587407 DOI: 10.1161/Circresaha.116.309506 |
0.496 |
|
| 2016 |
Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL. Biology of PCSK9: beyond LDL cholesterol lowering. Cardiovascular Research. PMID 27496869 DOI: 10.1093/Cvr/Cvw194 |
0.427 |
|
| 2016 |
Zhu L, Giunzioni I, Tavori H, Covarrubias R, Ding L, Zhang Y, Ormseth M, Major AS, Stafford JM, Linton MF, Fazio S. Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-α Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 27365402 DOI: 10.1161/Atvbaha.116.307736 |
0.423 |
|
| 2016 |
McDonagh M, Peterson K, Holzhammer B, Fazio S. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. Journal of Managed Care & Specialty Pharmacy. 22: 641-653q. PMID 27231792 DOI: 10.18553/Jmcp.2016.22.6.641 |
0.319 |
|
| 2016 |
Bartlett J, Predazzi IM, Williams SM, Bush WS, Kim Y, Havas S, Toth PP, Fazio S, Miller M. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study. Circulation. Cardiovascular Quality and Outcomes. PMID 27166203 DOI: 10.1161/Circoutcomes.115.002436 |
0.455 |
|
| 2016 |
Tavori H, Christian DC, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB, Lambert G, Tsimikas S, Fazio S. PCSK9 Association With Lipoprotein(a). Circulation Research. PMID 27121620 DOI: 10.1161/Circresaha.116.308811 |
0.456 |
|
| 2016 |
Babaev VR, Yeung M, Erbay E, Ding L, Zhang Y, May JM, Fazio S, Hotamisligil GS, Linton MF. Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 27102962 DOI: 10.1161/Atvbaha.116.307580 |
0.46 |
|
| 2016 |
Ormseth MJ, Yancey PG, Solus JF, Bridges SL, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ, Vickers KC, Kon V, Stein CM. Effect of drug therapy on net cholesterol efflux capacity of HDL-enriched serum in rheumatoid arthritis. Arthritis & Rheumatology (Hoboken, N.J.). PMID 26991245 DOI: 10.1002/Art.39675 |
0.355 |
|
| 2016 |
Tavori H, Giunzioni I, Predazzi IM, Plubell D, Miles J, DeVay RM, Liang H, Rashid S, Linton MF, Fazio S. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovascular Research. PMID 26980204 DOI: 10.1093/Cvr/Cvw053 |
0.509 |
|
| 2016 |
Shapiro MD, Fazio S. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Circulation Research. 118: 732-49. PMID 26892970 DOI: 10.1161/Circresaha.115.306471 |
0.436 |
|
| 2016 |
Babaev VR, Ding L, Zhang Y, May JM, Lin CP, Fazio S, Linton MF. Macrophage IκB Kinase α Deficiency Suppresses Akt Phosphorylation, Reduces Cell Survival, and Decreases Early Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 26848161 DOI: 10.1161/Atvbaha.115.306931 |
0.351 |
|
| 2016 |
Colantonio L, Fazio S, Rosenson R, Miller M, Banach M, Safford M, Muntner P, Toth P. LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INCIDENT CORONARY HEART DISEASE AMONG BLACKS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY Journal of the American College of Cardiology. 67: 1837. DOI: 10.1016/S0735-1097(16)31838-1 |
0.309 |
|
| 2015 |
Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S. Local Effects of Human PCSK9 on the Atherosclerotic Lesion. The Journal of Pathology. PMID 26333678 DOI: 10.1002/Path.4630 |
0.532 |
|
| 2015 |
Yamamoto S, Zhong J, Yancey PG, Zuo Y, Linton MF, Fazio S, Yang H, Narita I, Kon V. Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis. 242: 56-64. PMID 26184694 DOI: 10.1016/J.Atherosclerosis.2015.06.055 |
0.328 |
|
| 2015 |
Predazzi IM, Sobota RS, Sanna S, Bush WS, Bartlett J, Lilley JS, Linton MF, Schlessinger D, Cucca F, Fazio S, Williams SM. Sex-Specific Parental Effects on Offspring Lipid Levels. Journal of the American Heart Association. 4. PMID 26126546 DOI: 10.1161/Jaha.115.001951 |
0.324 |
|
| 2015 |
Tao H, Yancey PG, Babaev VR, Blakemore JL, Zhang Y, Ding L, Fazio S, Linton MF. Macrophage SR-BI Mediates Efferocytosis via Src/PI3K/Rac1 Signaling and Reduces Atherosclerotic Lesion Necrosis. Journal of Lipid Research. PMID 26059978 DOI: 10.1194/Jlr.M056689 |
0.432 |
|
| 2015 |
Kon V, Yang H, Fazio S. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Archives of Medical Research. 46: 379-91. PMID 26009251 DOI: 10.1016/J.Arcmed.2015.05.009 |
0.441 |
|
| 2015 |
Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S. Response to letter regarding article, "proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms". Circulation. 131: e428. PMID 25940973 DOI: 10.1161/Circulationaha.114.013729 |
0.386 |
|
| 2015 |
Coppola JA, Shrubsole MJ, Cai Q, Smalley WE, Dai Q, Ness RM, Fazio S, Zheng W, Murff HJ. Plasma lipid levels and colorectal adenoma risk. Cancer Causes & Control : Ccc. 26: 635-43. PMID 25761410 DOI: 10.1007/S10552-015-0555-Y |
0.363 |
|
| 2015 |
Guo L, Chen Z, Amarnath V, Yancey PG, Van Lenten BJ, Savage JR, Fazio S, Linton MF, Davies SS. Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts. Antioxidants & Redox Signaling. 22: 1633-45. PMID 25751734 DOI: 10.1089/Ars.2014.6078 |
0.429 |
|
| 2015 |
Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains. Current Atherosclerosis Reports. 17: 499. PMID 25712137 DOI: 10.1007/S11883-015-0499-4 |
0.371 |
|
| 2015 |
Fazio S. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe. Atherosclerosis. Supplements. 17: 23-6. PMID 25659873 DOI: 10.1016/S1567-5688(15)50006-8 |
0.497 |
|
| 2015 |
Tavori H, Su YR, Yancey PG, Giunzioni I, Wilhelm AJ, Blakemore JL, Zabalawi M, Linton MF, Sorci-Thomas MG, Fazio S. Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. Journal of Lipid Research. 56: 635-43. PMID 25593328 DOI: 10.1194/Jlr.M056408 |
0.509 |
|
| 2015 |
Tavori H, Rashid S, Fazio S. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis. 238: 264-70. PMID 25544176 DOI: 10.1016/J.Atherosclerosis.2014.12.017 |
0.444 |
|
| 2015 |
Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism: Clinical and Experimental. 64: 263-73. PMID 25467845 DOI: 10.1016/J.Metabol.2014.10.020 |
0.335 |
|
| 2014 |
Lee S, Amici S, Tavori H, Zeng WM, Freeland S, Fazio S, Notterpek L. PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 16140-52. PMID 25429154 DOI: 10.1523/Jneurosci.1908-14.2014 |
0.425 |
|
| 2014 |
Babaev VR, Hebron KE, Wiese CB, Toth CL, Ding L, Zhang Y, May JM, Fazio S, Vickers KC, Linton MF. Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. Journal of Lipid Research. 55: 2296-308. PMID 25240046 DOI: 10.1194/Jlr.M050633 |
0.429 |
|
| 2014 |
Tavori H, Fan D, Giunzioni I, Zhu L, Linton MF, Fogo AB, Fazio S. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. Journal of Lipid Research. 55: 2073-81. PMID 25183802 DOI: 10.1194/Jlr.M049874 |
0.486 |
|
| 2014 |
Fazio S, Tavori H. Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot. Circulation Research. 115: 472-4. PMID 25124321 DOI: 10.1161/Circresaha.114.304575 |
0.461 |
|
| 2014 |
Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation. 130: 431-41. PMID 25070550 DOI: 10.1161/Circulationaha.113.006720 |
0.483 |
|
| 2014 |
Tavori H, Giunzioni I, Linton MF, Fazio S. Response to Duell et al. Circulation Research. 115: e5. PMID 24951770 DOI: 10.1161/Circresaha.114.304199 |
0.306 |
|
| 2014 |
Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. Journal of the American College of Cardiology. 63: 1935-47. PMID 24632267 DOI: 10.1016/J.Jacc.2014.01.060 |
0.403 |
|
| 2014 |
Silver HJ, Kang H, Keil CD, Muldowney JA, Kocalis H, Fazio S, Vaughan DE, Niswender KD. Consuming a balanced high fat diet for 16 weeks improves body composition, inflammation and vascular function parameters in obese premenopausal women. Metabolism: Clinical and Experimental. 63: 562-73. PMID 24559846 DOI: 10.1016/J.Metabol.2014.01.004 |
0.306 |
|
| 2014 |
Prins PA, Hill MF, Airey D, Nwosu S, Perati PR, Tavori H, F Linton M, Kon V, Fazio S, Sampson UK. Angiotensin-induced abdominal aortic aneurysms in hypercholesterolemic mice: role of serum cholesterol and temporal effects of exposure. Plos One. 9: e84517. PMID 24465413 DOI: 10.1371/Journal.Pone.0084517 |
0.332 |
|
| 2014 |
Miller M, Kim Y, Havas S, Kwiterovich P, Fazio S. DOES LOW HDL-C INCREASE CHD RISK WHEN TG & LDL-C ARE NORMAL? THE FRAMINGHAM OFFSPRING STUDY Journal of the American College of Cardiology. 63: A1286. DOI: 10.1016/S0735-1097(14)61286-9 |
0.358 |
|
| 2014 |
Rashid S, Tavori H, Guinzioni I, Fazio S. PCSK9 promotes intestinal overproduction of apolipoprotein-b lipoproteins through ldl-receptor dependent and independent mechanisms Atherosclerosis. 235: e185. DOI: 10.1016/J.Atherosclerosis.2014.05.539 |
0.404 |
|
| 2014 |
Tavori H, Fan D, Yang S, Fogo AB, Linton MF, Fazio S. Expression of apoESendai by macrophages causes lipoprotein glomerulopathy while suppressing atherosclerosis Atherosclerosis. 233: 327. DOI: 10.1016/J.Atherosclerosis.2013.11.056 |
0.488 |
|
| 2013 |
Tavori H, Giunzioni I, Linton MF, Fazio S. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circulation Research. 113: 1290-5. PMID 24122718 DOI: 10.1161/Circresaha.113.302655 |
0.419 |
|
| 2013 |
Lilley JS, Linton MF, Fazio S. Oral retinoids and plasma lipids. Dermatologic Therapy. 26: 404-10. PMID 24099071 DOI: 10.1111/Dth.12085 |
0.372 |
|
| 2013 |
Fazio S, Linton MF. Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion. Circulation Research. 113: 94-6. PMID 23833288 DOI: 10.1161/Circresaha.113.301832 |
0.425 |
|
| 2013 |
Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 127: 2403-13. PMID 23690465 DOI: 10.1161/Circulationaha.113.001592 |
0.471 |
|
| 2013 |
Predazzi IM, Rokas A, Deinard A, Schnetz-Boutaud N, Williams ND, Bush WS, Tacconelli A, Friedrich K, Fazio S, Novelli G, Haines JL, Sirugo G, Williams SM. Putting pleiotropy and selection into context defines a new paradigm for interpreting genetic data. Circulation. Cardiovascular Genetics. 6: 299-307. PMID 23616601 DOI: 10.1161/Circgenetics.113.000126 |
0.313 |
|
| 2013 |
Kon V, Ikizler TA, Fazio S. Importance of high-density lipoprotein quality: evidence from chronic kidney disease. Current Opinion in Nephrology and Hypertension. 22: 259-65. PMID 23470818 DOI: 10.1097/Mnh.0B013E32835Fe47F |
0.342 |
|
| 2013 |
Ormseth MJ, Swift LL, Fazio S, Linton MF, Raggi P, Solus JF, Oeser A, Bian A, Gebretsadik T, Shintani A, Stein CM. Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus Lupus. 22: 26-33. PMID 23060481 DOI: 10.1177/0961203312462756 |
0.307 |
|
| 2013 |
Melone M, Tavori H, Giunzioni I, Davis H, Neff D, Fazio S, Rashid S. Physiological Levels of PCSK9 Promote Hepatic and Intestinal Overproduction of Apolipoprotein-B Lipoproteins Through LDl-Receptor Dependent and Independent Mechanisms Canadian Journal of Cardiology. 29: S169. DOI: 10.1016/J.Cjca.2013.07.257 |
0.393 |
|
| 2013 |
Melone M, Davis H, Ai X, Neff D, Fazio S, Rashid S. Pcsk9 Inhibition Augments the Therapeutic Effect of Ezetimibe in Lowering Intestinal Apolipoprotein B Lipoprotein Production Canadian Journal of Cardiology. 29: S378. DOI: 10.1016/J.Atherosclerosis.2014.05.774 |
0.346 |
|
| 2012 |
Fazio S, Linton MF. When it looks like familial hypercholesterolemia...but is not. Circulation. Cardiovascular Genetics. 5: 599-601. PMID 23250898 DOI: 10.1161/Circgenetics.112.965137 |
0.42 |
|
| 2012 |
Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. Journal of the American College of Cardiology. 60: 2372-9. PMID 23141484 DOI: 10.1016/J.Jacc.2012.09.013 |
0.369 |
|
| 2012 |
Fazio S, Linton MF. Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: a case for resistin. Journal of the American College of Cardiology. 59: 1706-8. PMID 22554601 DOI: 10.1016/J.Jacc.2012.01.034 |
0.436 |
|
| 2012 |
Fazio S, Linton MF. Inhibition of apolipoprotein(a) synthesis by farnesoid X receptor and fibroblast growth factor 15/19: a step toward selective lipoprotein(a) therapeutics. Arteriosclerosis, Thrombosis, and Vascular Biology. 32: 1060-2. PMID 22517359 DOI: 10.1161/Atvbaha.112.245571 |
0.493 |
|
| 2012 |
Prins PA, Perati PR, Kon V, Guo Z, Ramesh A, Linton MF, Fazio S, Sampson UK. Benzo[a]pyrene potentiates the pathogenesis of abdominal aortic aneurysms in apolipoprotein E knockout mice. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 29: 121-30. PMID 22415081 DOI: 10.1159/000337593 |
0.318 |
|
| 2012 |
Martinez MN, Emfinger CH, Overton M, Hill S, Ramaswamy TS, Cappel DA, Wu K, Fazio S, McDonald WH, Hachey DL, Tabb DL, Stafford JM. Obesity and altered glucose metabolism impact HDL composition in CETP transgenic mice: a role for ovarian hormones. Journal of Lipid Research. 53: 379-89. PMID 22215797 DOI: 10.1194/Jlr.M019752 |
0.407 |
|
| 2012 |
Levin MC, Lidberg U, Jirholt P, Adiels M, Wramstedt A, Gustafsson K, Greaves DR, Li S, Fazio S, Linton MF, Olofsson SO, Borén J, Gjertsson I. Evaluation of macrophage-specific promoters using lentiviral delivery in mice. Gene Therapy. 19: 1041-7. PMID 22130447 DOI: 10.1038/Gt.2011.195 |
0.341 |
|
| 2012 |
Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Current Atherosclerosis Reports. 14: 1-10. PMID 22102062 DOI: 10.1007/S11883-011-0219-7 |
0.463 |
|
| 2012 |
Fazio S. Recent insights into the pathogenesis of type III hyperlipoproteinemia. Trends in Cardiovascular Medicine. 3: 191-6. PMID 21244932 DOI: 10.1016/1050-1738(93)90005-Q |
0.429 |
|
| 2012 |
Tavori H, Fazio S, Linton MF. PCSK9, a novel target for lowering LDL cholesterol: Promise and progress Clinical Lipidology. 7: 611-615. DOI: 10.2217/Clp.12.72 |
0.402 |
|
| 2011 |
Fazio S, Linton MF. Low levels of high-density lipoprotein cholesterol due to lecithin:cholesterol acyltransferase mutations increase carotid atherosclerosis. Journal of the American College of Cardiology. 58: 2488-90. PMID 22133848 DOI: 10.1016/J.Jacc.2010.11.091 |
0.474 |
|
| 2011 |
Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 31: 2856-64. PMID 21979434 DOI: 10.1161/Atvbaha.111.237198 |
0.352 |
|
| 2011 |
Yancey PG, Ding Y, Fan D, Blakemore JL, Zhang Y, Ding L, Zhang J, Linton MF, Fazio S. Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent. Circulation. 124: 454-64. PMID 21730304 DOI: 10.1161/Circulationaha.111.032268 |
0.489 |
|
| 2011 |
Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Current Opinion in Cardiology. 26: 342-7. PMID 21499090 DOI: 10.1097/Hco.0B013E3283470359 |
0.326 |
|
| 2011 |
Babaev VR, Runner RP, Fan D, Ding L, Zhang Y, Tao H, Erbay E, Görgün CZ, Fazio S, Hotamisligil GS, Linton MF. Macrophage Mal1 deficiency suppresses atherosclerosis in low-density lipoprotein receptor-null mice by activating peroxisome proliferator-activated receptor-γ-regulated genes. Arteriosclerosis, Thrombosis, and Vascular Biology. 31: 1283-90. PMID 21474828 DOI: 10.1161/Atvbaha.111.225839 |
0.507 |
|
| 2011 |
Woo KV, Qu X, Babaev VR, Linton MF, Guzman RJ, Fazio S, Baldwin HS. Tie1 attenuation reduces murine atherosclerosis in a dose-dependent and shear stress-specific manner. The Journal of Clinical Investigation. 121: 1624-35. PMID 21383501 DOI: 10.1172/Jci42040 |
0.369 |
|
| 2011 |
Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev VR, Major AS, Linton MF, Fazio S, Hunley TE, Kon V, Fogo AB. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. American Journal of Physiology. Renal Physiology. 300: F1203-13. PMID 21367915 DOI: 10.1152/Ajprenal.00468.2010 |
0.374 |
|
| 2011 |
Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clinical Chemistry. 57: 392-410. PMID 21266551 DOI: 10.1373/Clinchem.2010.155333 |
0.414 |
|
| 2011 |
Yamamoto S, Zuo Y, Ma J, Yancey PG, Hunley TE, Motojima M, Fogo AB, Linton MF, Fazio S, Ichikawa I, Kon V. Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 26: 2491-7. PMID 21245127 DOI: 10.1093/Ndt/Gfq759 |
0.316 |
|
| 2011 |
Kon V, Linton MF, Fazio S. Atherosclerosis in chronic kidney disease: the role of macrophages. Nature Reviews. Nephrology. 7: 45-54. PMID 21102540 DOI: 10.1038/Nrneph.2010.157 |
0.447 |
|
| 2011 |
Babaev VR, Whitesell RR, Li L, Linton MF, Fazio S, May JM. Selective macrophage ascorbate deficiency suppresses early atherosclerosis. Free Radical Biology & Medicine. 50: 27-36. PMID 20974251 DOI: 10.1016/J.Freeradbiomed.2010.10.702 |
0.485 |
|
| 2011 |
Fazio S, Linton MF. Evidence-based Management of Lipid Disorders Clinical Lipidology. 6: 143-145. DOI: 10.2217/Clp.11.10 |
0.305 |
|
| 2011 |
Fazio S, Guyton J, Lin J, Tomassini J, Shah A, Tershakovec A. 82 COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB LEVELS IN HYPERLIPIDEMIC PATIENTS Atherosclerosis Supplements. 12: 20. DOI: 10.1016/S1567-5688(11)70083-6 |
0.329 |
|
| 2011 |
Brown W, Fazio S, Guyton J, Dong Q, Tomassini J, Shah A, Tershakovec A. 59 RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NONHDL-C, APOB AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN Atherosclerosis Supplements. 12: 14. DOI: 10.1016/S1567-5688(11)70060-5 |
0.303 |
|
| 2011 |
Fazio S, Guyton JR, Lin J, Tomassini JE, Shah AK, Tershakovec AM. COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LEVELS OF LDL-C, NON-HDL-C AND APO B IN HYPERLIPIDEMIC PATIENTS Journal of the American College of Cardiology. 57: E499. DOI: 10.1016/S0735-1097(11)60499-3 |
0.345 |
|
| 2011 |
Fazio S, Guyton J, Lin J, Tomassini J, Shah A, Tershakovec A. Ezetimibe/Simvastatin + Extended Release Niacin Therapy Improves Attainment of Recommended Levels of LDL-C, Non-HDL-C, and ApoB in Hyperlipidemic Patients † Journal of Clinical Lipidology. 5: 208-209. DOI: 10.1016/J.Jacl.2011.03.023 |
0.33 |
|
| 2011 |
Brown WV, Fazio S, Guyton J, Dong Q, Tomassini J, Jensen E, Shah A, Tershakovec A. Relationship Between HsCRP Reduction and LDL-C, Non-HDL-C, ApoB, and HDL-C in Hyperlipidemic Patients Treated with Ezetimibe/Simvastatin + Niaspan † Journal of Clinical Lipidology. 5: 206-207. DOI: 10.1016/J.Jacl.2011.03.021 |
0.335 |
|
| 2010 |
Fazio S, Linton MF. High-density lipoprotein therapeutics and cardiovascular prevention. Journal of Clinical Lipidology. 4: 411-9. PMID 21122685 DOI: 10.1016/J.Jacl.2010.08.004 |
0.449 |
|
| 2010 |
Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. The Journal of Biological Chemistry. 285: 36958-68. PMID 20847045 DOI: 10.1074/Jbc.M110.127829 |
0.415 |
|
| 2010 |
Linton MF, Fazio S. 6-Mercaptopurine, monocytes, and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 30: 1494-6. PMID 20631345 DOI: 10.1161/Atvbaha.110.208264 |
0.413 |
|
| 2010 |
Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. The American Journal of Cardiology. 105: 487-94. PMID 20152243 DOI: 10.1016/J.Amjcard.2009.10.001 |
0.381 |
|
| 2010 |
Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, Linton MF, Fazio S. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arteriosclerosis, Thrombosis, and Vascular Biology. 30: 787-95. PMID 20150557 DOI: 10.1161/Atvbaha.109.202051 |
0.79 |
|
| 2010 |
Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, Fazio S, Wiest MM, Watkins SM, Linton MF, Hotamisligil GS. Erratum: Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis Nature Medicine. 16: 237-237. DOI: 10.1038/Nm0210-237C |
0.392 |
|
| 2010 |
Kosiborod M, Spertus JA, Jones PG, Heidenreich PA, Kulkarni KR, Fazio S. HIGH HDL CHOLESTEROL LEVELS AND MARKERS OF INFLAMMATION AND METABOLIC HEALTH IN PATIENTS HOSPITALIZED WITH ACUTE MYOCARDIAL INFARCTION Journal of the American College of Cardiology. 55: A123.E1149. DOI: 10.1016/S0735-1097(10)61150-3 |
0.358 |
|
| 2009 |
Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, Fazio S, Wiest MM, Watkins SM, Linton MF, Hotamisligil GS. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nature Medicine. 15: 1383-91. PMID 19966778 DOI: 10.1038/Nm.2067 |
0.412 |
|
| 2009 |
Houston MC, Fazio S, Chilton FH, Wise DE, Jones KB, Barringer TA, Bramlet DA. Nonpharmacologic treatment of dyslipidemia. Progress in Cardiovascular Diseases. 52: 61-94. PMID 19732602 DOI: 10.1016/J.Pcad.2009.02.002 |
0.316 |
|
| 2009 |
Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutrition, Metabolism, and Cardiovascular Diseases : Nmcd. 20: 656-61. PMID 19699071 DOI: 10.1016/J.Numecd.2009.05.017 |
0.359 |
|
| 2009 |
Zuo Y, Yancey P, Castro I, Khan WN, Khan W, Motojima M, Ichikawa I, Fogo AB, Linton MF, Fazio S, Kon V. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arteriosclerosis, Thrombosis, and Vascular Biology. 29: 1277-82. PMID 19667109 DOI: 10.1161/Atvbaha.109.188995 |
0.321 |
|
| 2009 |
Jayagopal A, Su YR, Blakemore JL, Linton MF, Fazio S, Haselton FR. Quantum dot mediated imaging of atherosclerosis. Nanotechnology. 20: 165102. PMID 19420562 DOI: 10.1088/0957-4484/20/16/165102 |
0.336 |
|
| 2009 |
Fazio S, Linton MF. Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma. The Journal of Clinical Endocrinology and Metabolism. 94: 1081-3. PMID 19349471 DOI: 10.1210/Jc.2009-0344 |
0.489 |
|
| 2009 |
Fazio S, Guyton JR, Polis A, Adewale A, Tomassini JE, Tershakovec A. Long-term Effect of Triple Combination Ezetimibe/Simvastatin+Extended-Release Niacin on Cholesterol Content of Lipoprotein Subclasses in Hyperlipidemic Patients Journal of Clinical Lipidology. 3: 228-229. DOI: 10.1016/J.Jacl.2009.04.036 |
0.379 |
|
| 2009 |
Tomassini JE, Fazio S, Guyton J, Tershakovec A. Long-term Effect of Combination Ezetimibe/Simvastatin+Extended-Release Niacin on Cholesterol Content of Lipoprotein Subclasses in Patients with Hyperlipidemia Journal of Clinical Lipidology. 3: 225. DOI: 10.1016/J.Jacl.2009.04.029 |
0.384 |
|
| 2008 |
Linton MF, Fazio S. Cyclooxygenase products and atherosclerosis. Drug Discovery Today. Therapeutic Strategies. 5: 25-36. PMID 19343100 DOI: 10.1016/J.Ddstr.2008.05.006 |
0.384 |
|
| 2008 |
Babaev VR, Chew JD, Ding L, Davis S, Breyer MD, Breyer RM, Oates JA, Fazio S, Linton MF. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metabolism. 8: 492-501. PMID 19041765 DOI: 10.1016/J.Cmet.2008.09.005 |
0.479 |
|
| 2008 |
Su YR, Blakemore JL, Zhang Y, Linton MF, Fazio S. Lentiviral transduction of apoAI into hematopoietic progenitor cells and macrophages: applications to cell therapy of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 28: 1439-46. PMID 18497309 DOI: 10.1161/Atvbaha.107.160093 |
0.373 |
|
| 2008 |
Chung CP, Oeser A, Raggi P, Solus JF, Avalos I, Linton MF, Fazio S, Stein CM. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clinical Rheumatology. 27: 1227-33. PMID 18421545 DOI: 10.1007/S10067-008-0890-4 |
0.359 |
|
| 2008 |
Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology. 51: 1564-72. PMID 18420099 DOI: 10.1016/J.Jacc.2008.03.003 |
0.305 |
|
| 2008 |
Gaultier A, Arandjelovic S, Niessen S, Overton CD, Linton MF, Fazio S, Campana WM, Cravatt BF, Gonias SL. Regulation of tumor necrosis factor receptor-1 and the IKK-NF-kappaB pathway by LDL receptor-related protein explains the antiinflammatory activity of this receptor. Blood. 111: 5316-25. PMID 18369152 DOI: 10.1182/Blood-2007-12-127613 |
0.772 |
|
| 2008 |
Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clinical Therapeutics. 30: 294-306. PMID 18343268 DOI: 10.1016/J.Clinthera.2008.02.004 |
0.45 |
|
| 2008 |
Ali YS, Linton MF, Fazio S. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Current Opinion in Endocrinology, Diabetes, and Obesity. 15: 142-6. PMID 18316949 DOI: 10.1097/Med.0B013E3282F5Ff98 |
0.336 |
|
| 2008 |
Lee SA, Wen W, Xiang YB, Fazio S, Linton MF, Cai Q, Liu D, Zheng W, Shu XO. Stability and reliability of plasma level of lipid biomarkers and their correlation with dietary fat intake. Disease Markers. 24: 73-9. PMID 18219092 DOI: 10.1155/2008/347817 |
0.444 |
|
| 2008 |
Fan D, Yancey PG, Qiu S, Ding L, Weeber EJ, Linton MF, Fazio S. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 47: 1631-9. PMID 18197702 DOI: 10.1021/Bi7016359 |
0.422 |
|
| 2008 |
Babaev VR, Porro F, Linton MF, Fazio S, Baralle FE, Muro AF. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis. 197: 534-40. PMID 17897651 DOI: 10.1016/J.Atherosclerosis.2007.08.015 |
0.421 |
|
| 2008 |
Brown B, Fazio S, Guyton J, Polis A, Tomassini J, Tershakovec A. TIME AND DOSE-RELATED EFFECTS ON THE LIPID PROFILE IN HYPERLIPIDEMIA PATIENTS FOLLOWING TRIPLE COMBINATION THERAPY WITH EZETIMIBE/SIMVASTATIN + NIACIN Atherosclerosis Supplements. 9: 186-187. DOI: 10.1016/S1567-5688(08)70749-9 |
0.309 |
|
| 2008 |
Swift LL, Hasty AH, Linton MF, Fazio S. Apolipoprotein E and Reverse Cholesterol Transport: The Role of Recycling in Plasma and Intracellular Lipid Trafficking High-Density Lipoproteins: From Basic Biology to Clinical Aspects. 55-87. DOI: 10.1002/9783527625178.ch3 |
0.309 |
|
| 2007 |
Gustafsson M, Levin M, Skålén K, Perman J, Fridén V, Jirholt P, Olofsson SO, Fazio S, Linton MF, Semenkovich CF, Olivecrona G, Borén J. Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase. Circulation Research. 101: 777-83. PMID 17761930 DOI: 10.1161/Circresaha.107.149666 |
0.539 |
|
| 2007 |
Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 116: 1404-12. PMID 17724261 DOI: 10.1161/Circulationaha.106.684704 |
0.819 |
|
| 2007 |
Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus Journal of Rheumatology. 34: 1849-1854. PMID 17659756 |
0.309 |
|
| 2007 |
Suganuma E, Babaev VR, Motojima M, Zuo Y, Ayabe N, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques Journal of the American Society of Nephrology. 18: 2311-2319. PMID 17634441 DOI: 10.1681/Asn.2006090967 |
0.391 |
|
| 2007 |
Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 447: 959-65. PMID 17554340 DOI: 10.1038/Nature05844 |
0.356 |
|
| 2007 |
Fan D, Qiu S, Overton CD, Yancey PG, Swift LL, Jerome WG, Linton MF, Fazio S. Impaired secretion of apolipoprotein E2 from macrophages. The Journal of Biological Chemistry. 282: 13746-53. PMID 17341585 DOI: 10.1074/Jbc.M611754200 |
0.808 |
|
| 2007 |
Yancey PG, Yu H, Linton MF, Fazio S. A pathway-dependent on ApoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells Arteriosclerosis, Thrombosis, and Vascular Biology. 27: 1123-1131. PMID 17303773 DOI: 10.1161/Atvbaha.107.139592 |
0.509 |
|
| 2007 |
Overton CD, Yancey PG, Major AS, Linton MF, Fazio S. Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse. Circulation Research. 100: 670-7. PMID 17303763 DOI: 10.1161/01.Res.0000260204.40510.Aa |
0.817 |
|
| 2007 |
Yancey PG, Jerome WG, Yu H, Griffin EE, Cox BE, Babaev VR, Fazio S, Linton MF. Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI. Journal of Lipid Research. 48: 1140-9. PMID 17299204 DOI: 10.1194/Jlr.M600539-Jlr200 |
0.57 |
|
| 2006 |
Fazio S, Linton MF. Editorial: Sorting out the complexities of reverse cholesterol transport: CETP polymorphisms, HDL, and coronary disease Journal of Clinical Endocrinology and Metabolism. 91: 3273-3275. PMID 16960121 DOI: 10.1210/Jc.2006-1264 |
0.367 |
|
| 2006 |
Stanic AK, Stein CM, Morgan AC, Fazio S, Linton MF, Wakeland EK, Olsen NJ, Major AS. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythermatosus Proceedings of the National Academy of Sciences of the United States of America. 103: 7018-7023. PMID 16636270 DOI: 10.1073/Pnas.0602311103 |
0.404 |
|
| 2006 |
Baumgartl J, Baudler S, Scherner M, Babaev V, Makowski L, Suttles J, McDuffie M, Tobe K, Kadowaki T, Fazio S, Kahn CR, Hotamisligil GS, Krone W, Linton M, Brüning JC. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metabolism. 3: 247-56. PMID 16581002 DOI: 10.1016/J.Cmet.2006.02.010 |
0.362 |
|
| 2006 |
Braun NA, Mohler PJ, Weisgraber KH, Hasty AH, Linton MF, Yancey PG, Su YR, Fazio S, Swift LL. Intracellular trafficking of recycling apolipoprotein E in Chinese hamster ovary cells. Journal of Lipid Research. 47: 1176-86. PMID 16534141 DOI: 10.1194/Jlr.M500503-Jlr200 |
0.443 |
|
| 2006 |
Babaev VR, Ding L, Reese J, Morrow JD, Breyer MD, Dey SK, Fazio S, Linton MF. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation. 113: 108-17. PMID 16380543 DOI: 10.1161/Circulationaha.105.591537 |
0.421 |
|
| 2006 |
Suganuma E, Zuo Y, Ayabe N, Ma J, Babaev VR, Linton MF, Fazio S, Ichikawa I, Fogo AB, Kon V. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction Journal of the American Society of Nephrology. 17: 433-441. PMID 16371432 DOI: 10.1681/Asn.2005080883 |
0.348 |
|
| 2006 |
Yu H, Zhang W, Yancey PG, Koury MJ, Zhang Y, Fazio S, Linton MF. Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 26: 150-6. PMID 16269665 DOI: 10.1161/01.Atv.0000194096.89476.73 |
0.439 |
|
| 2006 |
Dove DE, Su YR, Swift LL, Linton MF, Fazio S. ACAT1 deficiency increases cholesterol synthesis in mouse peritoneal macrophages. Atherosclerosis. 186: 267-74. PMID 16144700 DOI: 10.1016/J.Atherosclerosis.2005.08.005 |
0.838 |
|
| 2006 |
Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawa I, Fazio S, Kon V. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice Atherosclerosis. 184: 312-321. PMID 16023123 DOI: 10.1016/J.Atherosclerosis.2005.05.016 |
0.403 |
|
| 2006 |
Baumgartl J, Baudler S, Scherner M, Babaev VR, Makowski L, Suttles J, McDuffie M, Tobe K, Kadowaki T, Fazio S, Kahn CR, Hotamisligil GS, Krone W, Linton MF, Brüning JC. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis (DOI:10.1016/j.cmet.2006.02.010) Cell Metabolism. 3: 469. DOI: 10.1016/J.Cmet.2006.05.008 |
0.323 |
|
| 2005 |
Zhu MY, Hasty AH, Harris C, Linton MF, Fazio S, Swift LL. Physiological relevance of apolipoprotein E recycling: studies in primary mouse hepatocytes. Metabolism: Clinical and Experimental. 54: 1309-15. PMID 16154429 DOI: 10.1016/J.Metabol.2005.04.019 |
0.523 |
|
| 2005 |
Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice Journal of Molecular and Cellular Cardiology. 39: 443-452. PMID 16040051 DOI: 10.1016/J.Yjmcc.2005.06.011 |
0.456 |
|
| 2005 |
Freeman NE, Rusinol AE, Linton M, Hachey DL, Fazio S, Sinensky MS, Thewke D. Acyl-coenzyme A:cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages. Journal of Lipid Research. 46: 1933-43. PMID 15995174 DOI: 10.1194/Jlr.M500101-Jlr200 |
0.387 |
|
| 2005 |
Gruen ML, Plummer MR, Zhang W, Posey KA, Linton MF, Fazio S, Hasty AH. Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I. Journal of Lipid Research. 46: 2007-14. PMID 15995171 DOI: 10.1194/Jlr.M500181-Jlr200 |
0.482 |
|
| 2005 |
Fazio S, Linton MF. Interplay between apolipoprotein E and scavenger receptor class B type I controls coronary atherosclerosis and lifespan in the mouse Circulation. 111: 3349-3351. PMID 15983260 DOI: 10.1161/Circulationaha.105.545996 |
0.528 |
|
| 2005 |
Burleigh ME, Babaev VR, Patel MB, Crews BC, Remmel RP, Morrow JD, Oates JA, Marnett LJ, Fazio S, Linton MF. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice Biochemical Pharmacology. 70: 334-342. PMID 15950196 DOI: 10.1016/J.Bcp.2005.04.044 |
0.41 |
|
| 2005 |
Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 1647-53. PMID 15947238 DOI: 10.1161/01.Atv.0000173413.31789.1A |
0.489 |
|
| 2005 |
Su YR, Dove DE, Major AS, Hasty AH, Boone B, Linton MF, Fazio S. Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1. Circulation. 111: 2373-81. PMID 15851589 DOI: 10.1161/01.Cir.0000164236.19860.13 |
0.839 |
|
| 2005 |
Hasty AH, Plummer MR, Weisgraber KH, Linton MF, Fazio S, Swift LL. The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I. Journal of Lipid Research. 46: 1433-9. PMID 15805547 DOI: 10.1194/Jlr.M400418-Jlr200 |
0.499 |
|
| 2005 |
Fazio S, Dove DE, Linton MF. ACAT inhibition: bad for macrophages, good for smooth muscle cells? Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 7-9. PMID 15626766 DOI: 10.1161/01.Atv.0000153086.46231.8C |
0.834 |
|
| 2005 |
Dove DE, Linton MF, Fazio S. ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects. American Journal of Physiology. Cell Physiology. 288: C586-92. PMID 15509658 DOI: 10.1152/Ajpcell.00210.2004 |
0.832 |
|
| 2005 |
Dove DE, Su YR, Zhang W, Jerome WG, Swift LL, Linton MF, Fazio S. ACAT1 deficiency disrupts cholesterol efflux and alters cellular morphology in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 128-34. PMID 15499044 DOI: 10.1161/01.Atv.0000148323.94021.E5 |
0.836 |
|
| 2005 |
Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 174-9. PMID 15499039 DOI: 10.1161/01.Atv.0000148548.47755.22 |
0.539 |
|
| 2004 |
Major AS, Wilson MT, McCaleb JL, Ru Su Y, Stanic AK, Joyce S, Van Kaer L, Fazio S, Linton MF. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 24: 2351-7. PMID 15472130 DOI: 10.1161/01.Atv.0000147112.84168.87 |
0.362 |
|
| 2004 |
Nobuhiko A, Suganuma E, Babaev VR, Fogo A, Swift LL, Linton MF, Fazio S, Ichikawa I, Kon V. Angiotensin II amplifies macrophage-driven atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 24: 2143-8. PMID 15374850 DOI: 10.1161/01.Atv.0000145607.03879.E0 |
0.328 |
|
| 2004 |
Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 110: 1492-8. PMID 15353487 DOI: 10.1161/01.Cir.0000141735.13202.B6 |
0.423 |
|
| 2004 |
Fazio S, Linton MF. Unique pathway for cholesterol uptake in fat cells Arteriosclerosis, Thrombosis, and Vascular Biology. 24: 1538-1539. PMID 15345518 DOI: 10.1161/01.Atv.0000140821.25572.1B |
0.504 |
|
| 2004 |
Linton MF, Major AS, Fazio S. Proatherogenic role for NK cells revealed Arteriosclerosis, Thrombosis, and Vascular Biology. 24: 992-994. PMID 15178571 DOI: 10.1161/01.Atv.0000128896.45976.F0 |
0.416 |
|
| 2004 |
Farkas MH, Weisgraber KH, Shepherd VL, Linton MF, Fazio S, Swift LL. The recycling of apolipoprotein E and its amino-terminal 22 kDa fragment: evidence for multiple redundant pathways. Journal of Lipid Research. 45: 1546-54. PMID 15145976 DOI: 10.1194/Jlr.M400104-Jlr200 |
0.445 |
|
| 2004 |
Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis Current Opinion in Pharmacology. 4: 116-123. PMID 15063354 DOI: 10.1016/J.Coph.2003.12.003 |
0.451 |
|
| 2004 |
Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy Current Atherosclerosis Reports. 6: 148-157. PMID 15023300 DOI: 10.1007/S11883-004-0104-8 |
0.43 |
|
| 2003 |
Fazio S, Linton MF. Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein? Mol Interv. 3: 436-440. PMID 14993451 DOI: 10.1124/Mi.3.8.436 |
0.504 |
|
| 2003 |
Linton MF, Fazio S. Macrophages, inflammation, and atherosclerosis International Journal of Obesity. 27. PMID 14704742 DOI: 10.1038/Sj.Ijo.0802498 |
0.546 |
|
| 2003 |
Zhang W, Yancey PG, Su YR, Babaev VR, Zhang Y, Fazio S, Linton MF. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 108: 2258-63. PMID 14581413 DOI: 10.1161/01.Cir.0000093189.97429.9D |
0.485 |
|
| 2003 |
Su YR, Ishiguro H, Major AS, Dove DE, Zhang W, Hasty AH, Babaev VR, Linton MF, Fazio S. Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters. Molecular Therapy : the Journal of the American Society of Gene Therapy. 8: 576-83. PMID 14529830 DOI: 10.1016/S1525-0016(03)00214-4 |
0.833 |
|
| 2003 |
Linton MF, Fazio S. A practical approach to risk assessment to prevent coronary artery disease and its complications American Journal of Cardiology. 92. PMID 12867251 DOI: 10.1016/S0002-9149(03)00505-8 |
0.317 |
|
| 2003 |
Raffaï RL, Hasty AH, Wang Y, Mettler SE, Sanan DA, Linton MF, Fazio S, Weisgraber KH. Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance. The Journal of Biological Chemistry. 278: 11670-5. PMID 12551940 DOI: 10.1074/Jbc.M212873200 |
0.422 |
|
| 2003 |
Farkas MH, Swift LL, Hasty AH, Linton MF, Fazio S. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. The Journal of Biological Chemistry. 278: 9412-7. PMID 12524433 DOI: 10.1074/Jbc.M208026200 |
0.459 |
|
| 2003 |
Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis Current Opinion in Internal Medicine. 2: 34-41. DOI: 10.1097/00132980-200302010-00007 |
0.437 |
|
| 2002 |
Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, Davidson JM, Linton MF, Fazio S, Homma T, Yoshida H, Ichikawa I. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. The Journal of Clinical Investigation. 110: 1859-68. PMID 12488436 DOI: 10.1172/Jci15045 |
0.359 |
|
| 2002 |
Su YR, Linton MF, Fazio S. Rapid quantification of murine ABC mRNAs by real time reverse transcriptase-polymerase chain reaction Journal of Lipid Research. 43: 2180-2187. PMID 12454281 DOI: 10.1194/Jlr.D200020-Jlr200 |
0.406 |
|
| 2002 |
Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice Arteriosclerosis, Thrombosis, and Vascular Biology. 22: 1892-1898. PMID 12426221 DOI: 10.1161/01.Atv.0000039169.47943.Ee |
0.422 |
|
| 2002 |
Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia Arteriosclerosis, Thrombosis, and Vascular Biology. 22: 1686-1691. PMID 12377750 DOI: 10.1161/01.Atv.0000033090.81345.E6 |
0.439 |
|
| 2002 |
Fazio S, Babaev VR, Burleigh ME, Major AS, Hasty AH, Linton MF. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. Journal of Lipid Research. 43: 1602-9. PMID 12364544 DOI: 10.1194/Jlr.M200108-Jlr200 |
0.496 |
|
| 2002 |
Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis Current Opinion in Lipidology. 13: 497-504. PMID 12352013 DOI: 10.1097/00041433-200210000-00005 |
0.454 |
|
| 2002 |
Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice Circulation. 105: 1816-1823. PMID 11956125 DOI: 10.1161/01.Cir.0000014927.74465.7F |
0.457 |
|
| 2002 |
Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: Emerging roles in metabolism and atherosclerosis Current Opinion in Lipidology. 13: 141-147. PMID 11891416 DOI: 10.1097/00041433-200204000-00005 |
0.333 |
|
| 2001 |
Yoshida H, Hasty AH, Major AS, Ishiguro H, Su YR, Gleaves LA, Babaev VR, Linton MF, Fazio S. Isoform-specific effects of apolipoprotein E on atherogenesis gene transduction studies in mice Circulation. 104: 2820-2825. PMID 11733401 DOI: 10.1161/Hc4801.100034 |
0.408 |
|
| 2001 |
Major AS, Dove DE, Ishiguro H, Su YR, Brown AM, Liu L, Carter KJ, Linton MF, Fazio S. Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 21: 1790-5. PMID 11701467 DOI: 10.1161/Hq1101.097798 |
0.846 |
|
| 2001 |
Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis Current Opinion in Lipidology. 12: 489-495. PMID 11561167 DOI: 10.1097/00041433-200110000-00003 |
0.424 |
|
| 2001 |
Ishiguro H, Yoshida H, Major AS, Zhu T, Babaev VR, Linton MF, Fazio S. Retrovirus-mediated Expression of Apolipoprotein A-I in the Macrophage Protects against Atherosclerosis in Vivo Journal of Biological Chemistry. 276: 36742-36748. PMID 11477092 DOI: 10.1074/Jbc.M106027200 |
0.484 |
|
| 2001 |
Fazio S, Linton MF. The inflamed plaque: Cytokine production and cellular cholesterol balance in the vessel wall American Journal of Cardiology. 88. PMID 11473738 DOI: 10.1016/S0002-9149(01)01717-9 |
0.513 |
|
| 2001 |
Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis Nature Medicine. 7: 699-705. PMID 11385507 DOI: 10.1038/89076 |
0.474 |
|
| 2001 |
Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats Kidney International. 59: 1899-1910. PMID 11318962 DOI: 10.1046/J.1523-1755.2001.0590051899.X |
0.308 |
|
| 2001 |
Swift LL, Farkas MH, Major AS, Valyi-Nagy K, Linton MF, Fazio S. A recycling pathway for resecretion of internalized apolipoprotein E in liver cells. The Journal of Biological Chemistry. 276: 22965-70. PMID 11304532 DOI: 10.1074/Jbc.M100172200 |
0.441 |
|
| 2001 |
Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis Frontiers in Bioscience : a Journal and Virtual Library. 6. PMID 11229870 DOI: 10.2741/FAZIO |
0.349 |
|
| 2001 |
Fazio S, Major AS, Swift LL, Gleaves LA, Accad M, Linton MF, Farese RV. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages Journal of Clinical Investigation. 107: 163-171. PMID 11160132 DOI: 10.1172/Jci10310 |
0.54 |
|
| 2001 |
Fazio S, Linton MF. Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low" Current Controlled Trials in Cardiovascular Medicine. 2: 8-11. DOI: 10.1186/Cvm-2-1-008 |
0.45 |
|
| 2000 |
Fazio S, Linton MF, Swift LL. The cell biology and physiologic relevance of ApoE recycling Trends in Cardiovascular Medicine. 10: 23-30. PMID 11150725 DOI: 10.1016/S1050-1738(00)00033-5 |
0.488 |
|
| 2000 |
Linton MF, Fazio S. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk Current Atherosclerosis Reports. 2: 29-35. PMID 11122722 DOI: 10.1007/S11883-000-0092-2 |
0.463 |
|
| 2000 |
Babaev VR, Gleaves LA, Carter KJ, Suzuki H, Kodama T, Fazio S, Linton MF. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A Arteriosclerosis, Thrombosis, and Vascular Biology. 20: 2593-2599. PMID 11116058 DOI: 10.1161/01.Atv.20.12.2593 |
0.381 |
|
| 2000 |
Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice Journal of Biological Chemistry. 275: 26293-26299. PMID 10858435 DOI: 10.1074/Jbc.M002423200 |
0.461 |
|
| 2000 |
Accad M, Smith SJ, Newland DL, Sanan DA, King LE, Linton MF, Fazio S, Farese RV. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1 Journal of Clinical Investigation. 105: 711-719. PMID 10727439 DOI: 10.1172/Jci9021 |
0.51 |
|
| 2000 |
Maron DJ, Fazio S, Linton MF. Current perspectives on statins Circulation. 101: 207-213. PMID 10637210 DOI: 10.1161/01.Cir.101.2.207 |
0.443 |
|
| 1999 |
Montine TJ, Montine KS, Olson SJ, Graham DG, Roberts LJ, Morrow JD, Linton MF, Fazio S, Swift LL. Increased cerebral cortical lipid peroxidation and abnormal phospholipids in aged homozygous apoE-deficient C57BL/6J mice. Experimental Neurology. 158: 234-41. PMID 10448437 DOI: 10.1006/Exnr.1999.7067 |
0.4 |
|
| 1999 |
Linton MF, Babaev VR, Gleaves LA, Fazio S. A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation Journal of Biological Chemistry. 274: 19204-19210. PMID 10383427 DOI: 10.1074/Jbc.274.27.19204 |
0.507 |
|
| 1999 |
Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo Journal of Clinical Investigation. 103: 1697-1705. PMID 10377176 DOI: 10.1172/Jci6117 |
0.485 |
|
| 1999 |
Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. The Journal of Clinical Investigation. 103: 1597-604. PMID 10359569 DOI: 10.1172/Jci5897 |
0.463 |
|
| 1999 |
Hasty AH, Linton MF, Brandt SJ, Babaev VR, Gleaves LA, Fazio S. Retroviral gene therapy in apoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation Circulation. 99: 2571-2576. PMID 10330390 DOI: 10.1161/01.Cir.99.19.2571 |
0.481 |
|
| 1999 |
Linton MF, Fazio S. Macrophages, lipoprotein metabolism, and atherosclerosis: Insights from murine bone marrow transplantation studies Current Opinion in Lipidology. 10: 97-105. PMID 10327277 DOI: 10.1097/00041433-199904000-00003 |
0.399 |
|
| 1999 |
Fazio S, Linton MF, Hasty AH, Swift LL. Recycling of apolipoprotein E in mouse liver Journal of Biological Chemistry. 274: 8247-8253. PMID 10075730 DOI: 10.1074/Jbc.274.12.8247 |
0.505 |
|
| 1999 |
Zuliani G, Arca M, Signore A, Bader G, Fazio S, Chianelli M, Bellosta S, Campagna F, Montali A, Maioli M, Pacifico A, Ricci G, Fellin R. Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 19: 802-9. PMID 10073989 DOI: 10.1161/01.Atv.19.3.802 |
0.429 |
|
| 1998 |
Fazio S, Linton MF, Grundy SM. On the relationship between cholesterol lowering and coronary disease event rate [5] (multiple letters) Circulation. 98: 2645-2646. PMID 9843480 DOI: 10.1161/01.Cir.98.23.2645 |
0.388 |
|
| 1998 |
Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor Journal of Clinical Investigation. 101: 1726-1736. PMID 9541504 DOI: 10.1172/Jci2181 |
0.46 |
|
| 1997 |
Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, Atkinson JB, Linton MF. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proceedings of the National Academy of Sciences of the United States of America. 94: 4647-52. PMID 9114045 DOI: 10.1073/Pnas.94.9.4647 |
0.522 |
|
| 1996 |
Fazio S, Linton MF. Murine bone marrow transplantation as a novel approach to studying the role of macrophages in lipoprotein metabolism and atherogenesis Trends in Cardiovascular Medicine. 6: 58-65. DOI: 10.1016/1050-1738(96)00007-2 |
0.506 |
|
| 1995 |
Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation Science. 267: 1034-1037. PMID 7863332 DOI: 10.1126/Science.7863332 |
0.416 |
|
| 1995 |
Fazio S, Yao Z. The enhanced association of apolipoprotein E with apolipoprotein B-containing lipoproteins in serum-stimulated hepatocytes occurs intracellularly. Arteriosclerosis, Thrombosis, and Vascular Biology. 15: 593-600. PMID 7749873 DOI: 10.1161/01.Atv.15.5.593 |
0.486 |
|
| 1994 |
Fazio VM, Fazio S, Rinaldi M, Catani MV, Zotti S, Ciafrè SA, Seripa D, Ricci G, Farace MG. Accumulation of human apolipoprotein-E in rat plasma after in vivo intramuscular injection of naked DNA. Biochemical and Biophysical Research Communications. 200: 298-305. PMID 8166698 DOI: 10.1006/Bbrc.1994.1448 |
0.315 |
|
| 1994 |
Fazio S, Sanan DA, Lee YL, Ji ZS, Mahley RW, Rall SC. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cys142). Arteriosclerosis and Thrombosis : a Journal of Vascular Biology. 14: 1873-9. PMID 7947615 DOI: 10.1161/01.Atv.14.11.1873 |
0.471 |
|
| 1993 |
Yao Z, Lauer SJ, Sanan DA, Fazio S. ApoA-IV is secreted on discrete HDL particles by the rat hepatoma cell line McA-RH7777 transfected with ApoA-IV cDNA. Arteriosclerosis and Thrombosis : a Journal of Vascular Biology. 13: 1476-86. PMID 8399085 DOI: 10.1161/01.Atv.13.10.1476 |
0.442 |
|
| 1993 |
Fazio S, Lee YL, Ji ZS, Rall SC. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. The Journal of Clinical Investigation. 92: 1497-503. PMID 8376602 DOI: 10.1172/Jci116728 |
0.427 |
|
| 1991 |
Gaddi A, Arca M, Ciarrocchi A, Fazio S, D'Alò G, Tiozzo R, Descovich GC, Calandra S. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS. Metabolism: Clinical and Experimental. 40: 1074-8. PMID 1658544 DOI: 10.1016/0026-0495(91)90132-G |
0.356 |
|
| Show low-probability matches. |